{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:41:44Z","timestamp":1767840104741,"version":"3.49.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6S","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>Rotavirus (RV) is the leading cause of severe gastroenteritis in young children. However, because the incorporation of live-attenuated RV vaccines as part routine childhood immunization schedules, the rates of hospitalization from RV infections have decreased significantly across the globe. While RV vaccine safety and effectiveness have been well documented in the general population, there is controversy surrounding its use in preterm and immunocompromised infants. In this article, we review current research and consensus statements on the safety of the RV vaccine, the immunogenicity of the response and the potential for transmission and shedding of the virus postvaccination in both preterm infants and immunocompromised infants. RV vaccines are well tolerated in hospitalized preterm infants with no significant increase in nosocomial infections, gastrointestinal complications or feeding difficulties. In select immunocompromised infants (such as HIV-infected or HIV-exposed infants), RV vaccine administration did not increase the rate of adverse events. However, multiple case reports noted increased rates of adverse events in infants with severe combined immunodeficiency. The risk of viral shedding and transmission between vaccinated neonates and household contacts remain low and does not outweigh the benefit of vaccination.<\/jats:p>","DOI":"10.1097\/inf.0000000000002322","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T03:40:57Z","timestamp":1560570057000},"page":"S43-S46","source":"Crossref","is-referenced-by-count":16,"title":["Dilemmas With Rotavirus Vaccine: The Neonate and Immunocompromised"],"prefix":"10.1097","volume":"38","author":[{"given":"Melissa","family":"Chiu","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Bao","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Sadarangani","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Center, BC Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada AND Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa052434","article-title":"Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.","volume":"354","author":"Ruiz-Palacios","year":"2006","journal-title":"N Engl J Med"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5694\/mja12.10062","article-title":"Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program.","volume":"197","author":"Dey","year":"2012","journal-title":"Med J Aust"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.vaccine.2015.03.016","article-title":"Effectiveness and impact of rotavirus vaccines in Europe, 2006-2014.","volume":"33","author":"Karafillakis","year":"2015","journal-title":"Vaccine"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1000446","article-title":"Rotavirus vaccine and health care utilization for diarrhea in U.S. children.","volume":"365","author":"Cortes","year":"2011","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"R5-20230912","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1086\/431512","article-title":"More on RotaShield and intussusception: the role of age at the time of vaccination.","volume":"192","author":"Simonsen","year":"2005","journal-title":"J Infect Dis"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/00006454-200212000-00003","article-title":"Clinical manifestations of rotavirus infection in the neonatal intensive care unit.","volume":"21","author":"Sharma","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/INF.0b013e3182490a2c","article-title":"Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.","volume":"31","author":"Omenaca","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1128\/CVI.00265-14","article-title":"Impact of rotavirus vaccine on premature infants.","volume":"21","author":"Rou\u00e9","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"e1555","DOI":"10.1542\/peds.2013-3504","article-title":"Safety of rotavirus vaccine in the NICU.","volume":"133","author":"Monk","year":"2014","journal-title":"Pediatrics"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1016\/j.vaccine.2010.05.057","article-title":"Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe.","volume":"28","author":"Vesikari","year":"2010","journal-title":"Vaccine"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/INF.0b013e31814521cb","article-title":"Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.","volume":"26","author":"Goveia","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"e1011","DOI":"10.1542\/peds.2011-2779","article-title":"Nosocomial rotavirus infections: a meta-analysis.","volume":"129","author":"Bruijning-Verhagen","year":"2012","journal-title":"Pediatrics"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"8141","DOI":"10.1016\/j.vaccine.2011.08.028","article-title":"Rotavirus shedding in premature infants following first immunization.","volume":"29","author":"Smith","year":"2011","journal-title":"Vaccine"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1016\/j.vaccine.2011.10.015","article-title":"Horizontal transmission of a human rotavirus vaccine strain\u2014a randomized, placebo-controlled study in twins.","volume":"29","author":"Rivera","year":"2011","journal-title":"Vaccine"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/infdis\/jix590","article-title":"Rotavirus vaccination can be performed without viral dissemination in the neonatal intensive care unit.","volume":"217","author":"Hiramatsu","year":"2018","journal-title":"J Infect Dis"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.vaccine.2013.08.041","article-title":"Comparison of virus shedding after lived attenuated and pentavalent reassortant rotavirus vaccine.","volume":"32","author":"Hsieh","year":"2014","journal-title":"Vaccine"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1473-3099(08)70231-7","article-title":"Rotavirus vaccines: viral shedding and risk of transmission.","volume":"8","author":"Anderson","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"e662","DOI":"10.1542\/peds.2013-0291","article-title":"Rotavirus vaccination of very low birth weight infants at discharge from the NICU.","volume":"132","author":"Stumpf","year":"2013","journal-title":"Pediatrics"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"e20171110","DOI":"10.1542\/peds.2017-1110","article-title":"Risk of rotavirus nosocomial spread after inpatient pentavalent rotavirus vaccination.","volume":"141","author":"Hofstetter","year":"2018","journal-title":"Pediatrics"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1016\/j.vaccine.2015.08.015","article-title":"Evaluation of pentavalent rotavirus vaccination in neonatal intensive care units.","volume":"33","author":"Thrall","year":"2015","journal-title":"Vaccine"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.vaccine.2017.01.048","article-title":"Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation\u2014a systematic review of randomized trials, observational studies and case reports.","volume":"35","author":"Croce","year":"2017","journal-title":"Vaccine"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1016\/j.vaccine.2010.07.039","article-title":"Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS).","volume":"28","author":"Bakare","year":"2010","journal-title":"Vaccine"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa0904485","article-title":"Vaccine-acquired rotavirus in infants with severe combined immunodeficiency.","volume":"362","author":"Patel","year":"2010","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"R24-20230912","doi-asserted-by":"crossref","first-page":"A61","DOI":"10.1016\/j.vaccine.2011.09.026","article-title":"Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(\u00ae), in Kenya, including among HIV-infected and HIV-exposed infants.","volume":"30","author":"Laserson","year":"2012","journal-title":"Vaccine"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/QAD.0000000000001258","article-title":"Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa.","volume":"31","author":"Levin","year":"2017","journal-title":"AIDS"},{"key":"R27-20230912","first-page":"1","article-title":"Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"58","author":"Cortese","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.gtc.2014.05.005","article-title":"The use of biologic agents in pregnancy and breastfeeding.","volume":"43","author":"Horst","year":"2014","journal-title":"Gastroenterol Clin North Am"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","article-title":"Case Report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn\u2019s disease.","volume":"4","author":"Cheent","year":"2010","journal-title":"J Crohns Colitis"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cgh.2017.08.041","article-title":"Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines.","volume":"16","author":"Beaulieu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3389\/fimmu.2017.01123","article-title":"Immunological changes in blood of newborns exposed to anti-TNF-\u03b1 during pregnancy.","volume":"8","author":"Esteve-Sol\u00e9","year":"2017","journal-title":"Front Immunol"},{"key":"R33-20230912","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjx180.031","article-title":"OP032 Outcome of pregnancies in female IBD patients treated with vedolizumab.","author":"Moens","year":"2018","journal-title":"yEuropean Crohn\u2019s and Colitis Organization"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"e12951","DOI":"10.1111\/tid.12951","article-title":"Safe administration of rotavirus vaccine in a cohort of infants exposed to immunosuppressive drugs during gestation.","volume":"20","author":"Dinelli","year":"2018","journal-title":"Transpl Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201906001-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:18:36Z","timestamp":1694557116000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201906001-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":32,"journal-issue":{"issue":"6S","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002322","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}